Published in Mov Disord on October 31, 2012
The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther (2014) 0.88
The Concept of Prodromal Parkinson's Disease. J Parkinsons Dis (2015) 0.81
Prediction of Parkinson's disease subsequent to severe depression: a ten-year follow-up study. J Neural Transm (Vienna) (2014) 0.78
Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease. J Neurol (2013) 0.78
Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. Front Aging Neurosci (2016) 0.78
Biomarkers in Parkinson's disease: Advances and strategies. Parkinsonism Relat Disord (2015) 0.77
Autonomic dysfunction in subjects at high risk for Parkinson's disease. J Neurol (2015) 0.77
Hand function is impaired in healthy older adults at risk of Parkinson's disease. J Neural Transm (Vienna) (2014) 0.76
Is there a need to redefine Parkinson's disease? J Neural Transm (Vienna) (2013) 0.76
Predictors of Parkinson's disease--not quite sound. Mov Disord (2013) 0.75
History of Illicit Stimulant Use Is Not Associated with Long-Lasting Changes in Learning of Fine Motor Skills in Humans. Neural Plast (2015) 0.75
Cognitive Performance Patterns in Healthy Individuals with Substantia Nigra Hyperechogenicity and Early Parkinson's Disease. Front Aging Neurosci (2016) 0.75
Genetic and constitutional factors are major contributors to substantia nigra hyperechogenicity. Sci Rep (2017) 0.75
Echogenicity of basal ganglia structures in different Huntington's disease phenotypes. J Neural Transm (Vienna) (2014) 0.75
Potential impact of self-perceived prodromal symptoms on the early diagnosis of Parkinson's disease. J Neurol (2013) 0.75
Brainstem raphe and substantia nigra echogenicity in idiopathic REM sleep behavior disorder with comorbid depression. J Neurol (2015) 0.75
Clinical characteristics related to worsening of motor function assessed by the Unified Parkinson's Disease Rating Scale in the elderly population. J Neurol (2014) 0.75
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med (2006) 8.12
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (2012) 6.61
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med (2002) 6.00
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci (2007) 5.68
Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res (2010) 5.08
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord (2004) 4.83
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Early consolidation in human primary motor cortex. Nature (2002) 3.56
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
Telomere length and risk of incident cancer and cancer mortality. JAMA (2010) 3.55
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol (2010) 3.15
Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol (2011) 3.01
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes (2004) 2.89
Influences on the reduction of relative telomere length over 10 years in the population-based Bruneck Study: introduction of a well-controlled high-throughput assay. Int J Epidemiol (2009) 2.87
Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord (2006) 2.81
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol (2012) 2.59
Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol (2012) 2.59
Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis: a population-based, prospective study. J Am Coll Cardiol (2008) 2.56
The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol (2008) 2.42
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain (2005) 2.40
Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol (2005) 2.40
Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood (2009) 2.40
Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord (2010) 2.34
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Neurological outcome of septic cardioembolic stroke after infective endocarditis. Stroke (2006) 2.31
Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord (2009) 2.28
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet (2005) 2.28
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 2.26
Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med (2006) 2.26
Olfactory dysfunction: common in later life and early warning of neurodegenerative disease. Dtsch Arztebl Int (2013) 2.22
Circulating microRNAs as novel biomarkers for platelet activation. Circ Res (2013) 2.22
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell (2013) 2.22
Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene. Ann Neurol (2009) 2.21
Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology (2012) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord (2008) 2.15
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord (2004) 2.13
Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem (2007) 2.12
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry (2009) 2.09
High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med (2006) 2.09
Seminar on choreas. Lancet Neurol (2006) 2.09
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation (2004) 2.08
Mechanical recanalization with flow restoration in acute ischemic stroke: the ReFlow (mechanical recanalization with flow restoration in acute ischemic stroke) study. JACC Cardiovasc Interv (2013) 2.05
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol (2008) 2.04
Multiple system atrophy. Lancet Neurol (2004) 2.04
Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care (2007) 2.03
Levodopa: 50 years of a revolutionary drug for Parkinson disease. Mov Disord (2014) 1.99
Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet (2002) 1.98
The diagnosis of Parkinson's disease. Lancet Neurol (2006) 1.97
Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord (2007) 1.96
Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J (2007) 1.94
Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurol (2012) 1.93